[RECORDING] The Patient Perspective: Evaluating Time and Treatment While Living with Metastatic Breast Cancer

Time is a precious resource for patients undergoing treatment for ER+, HER2- metastatic breast cancer (mBC). The time commitment needed to attend appointments with their oncologist, finding a loved one to accompany them to appointments, taking time off from work, and rescheduling personal appointments contribute to the burden these patients experience.

A recent Ipsos survey, conducted in collaboration with Living Beyond Breast Cancer and funded by Eli Lilly and Company, highlights the time-burden patients with ER+, HER2- mBC face when attending appointments, and explores their experiences and treatment preferences. Ipsos also analyzed conversations on social media to gain insights into the experiences of patients living with ER+, HER2- mBC

Hear breast cancer expert from Ipsos, Eric Blouin, and CEO of Living Beyond Breast Cancer, Jean Sachs, dive into the findings and implications of this research, including:

  • Time commitment required by patients to attend appointments with their oncologist
  • The accommodations necessary for patients to attend these appointments
  • Treatment preferences, and their perceptions of benefits & draw backs of oral medications vs. intramuscular (IM) injections